Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: ANI Pharmaceuticals 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: ANI Pharmaceuticals 1Q

Revenues up 72% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ANI Pharmaceuticals
 
1Q Revenues: $18.8 million (+72%)

1Q Earnings: $4.4 million (+30%)

Comments: Generic sales were up 52% to $12.3 million primarily due to increased sales of EEMT, as well as Methazolamide and Etodolac products, which launched in 4Q14 and 1Q15, respectively. Branded pharmaceutical sales increased 452% to $4.3 million, driven by sales of Lithobid and Vancocin, which were acquired in 3Q14. Contract manufacturing revenue was down 26% to $1.2 million as a result of timing of customer orders. Contract services and other revenues increased 136% to $1.1 million due to royalties from the authorized generic of Vancocin.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics